diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md
index ab8271fe..3cb24192 100644
--- a/pages/STOP2030___Web.md
+++ b/pages/STOP2030___Web.md
@@ -38,15 +38,15 @@
 			- No stopping rules were reached
 			- Safety was adequate
 			- Palatability results confirm adecuacy of size, taste and smell
-			- Superior efficacy against T. trichiura confirm
+			- Superior efficacy against T. trichiura confirms a comprehensive spectrum against STH
 		- ## Otros facts
 			- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
-		- Investigadores principales de cada uno de los partners
-		- Ideas generales importantes
 			- Dosing strategies for Ivermectine are being revisited
 			- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies
 			- Acceptability and safety studies are underway
 			- The access plan is being developed
+		- Investigadores principales de cada uno de los partners
+		- Ideas generales importantes
 			- Integration across programs (these results have implications beyond STH)
 			- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
 		- El abstract del proyecto?